Abstract

BackgroundGlioma is a major type of brain cancer and responsible for high death rate worldwide due to the delayed diagnosis and chemo-resistance. It is responsible for nearly 16% of all brain cancer incidences with increased prevalence globally.ObjectiveThe present research study deals with discovering the in vitro anticancer potential of cirsilineol on the rat glioma C6 cells through the inhibition of PI3K/Akt/mTOR and MAPK signaling pathways.MethodologyThe in vitro antioxidant potential of cirsilineol was examined by different free radical scavenging analyses. The effects of cirsilineol on the cell viability of C6 and normal Vero cells were investigated by MTT assay. The intracellular ROS production and apoptotic cell death in the cirsilineol-administered C6 cells were scrutinized by fluorescent staining techniques. The contents of TBARS and GSH, SOD and caspase activity were examined using assay kits. The PI3K, mTOR, Akt, ERK1/2, JNK1/2, and p38 expressions in the cirsilineol-supplemented C6 cells were examined by RT-PCR study.ResultsThe cirsilineol treatment appreciably scavenged the DPPH, superoxide, and peroxyl radicals. The cell viability of C6 cells was markedly reduced by the cirsilineol; however, it does not affected the Vero cell viability. The cirsilineol treatment demonstrated the augmented ROS production and apoptosis in the C6 cells. The TBARS level and caspase activity were improved, and GSH level and SOD activity were depleted by the cirsilineol. Cirsilineol effectively inhibited PI3K, mTOR, Akt, ERK1/2, JNK1/2, and p38 expressions in the C6 cells.ConclusionOur findings confirmed that the cirsilineol inhibited cell growth and induced apoptosis in C6 cells by inhibiting the PI3K/Akt/mTOR and MAPK signaling cascades. Hence, it can be a potential candidate to treat the glioma in the future.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call